Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metasta...

詳細記述

保存先:
書誌詳細
出版年:Int J Clin Oncol
主要な著者: Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, Uemura, Hiroji
フォーマット: Artigo
言語:Inglês
出版事項: Springer Japan 2017
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809574/
https://ncbi.nlm.nih.gov/pubmed/28770408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-017-1176-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料